OBJECTIVES: To study the natural course of viremia during primary HIV infection (PHI). METHOD: Eight patients were followed from a median of 5 days from the onset of PHI illness. Plasma HIV-1 RNA levels were measured frequently and the results were fitted to mathematical models. HIV-1 RNA levels were also monitored in nine patients given two reverse transcriptase inhibitors and a protease inhibitor after a median of 7 days from the onset of PHI illness. RESULTS: HIV-1 RNA appeared in the blood during the week preceding onset of PHI illness and increased rapidly during the first viremic phase, reaching a peak at a mean of 7 days after onset of illness. This was followed by a phase of rapidly decreasing levels of HIV-1 RNA to an average of 21 days after onset. Viral density continued to decline thereafter but at a 5- to 50-fold lower rate; a steady-state level was reached at a median of 2 months after onset of PHI. Peak viral density levels correlated significantly with levels measured between days 50 and 600. Initiation of antiretroviral treatment during PHI resulted in rapidly declining levels to below 50 copies/mL. CONCLUSIONS: This study demonstrates the kinetic phases of viremia during PHI and indicates two new contributions to the natural history of HIV-1 infection: PHI peak levels correlate with steady-state levels and HIV-1 RNA declines biphasically; an initial rapid decay is usually followed by a slow decay, which is similar to the initial changes seen with antiviral treatment.
OBJECTIVES: To study the natural course of viremia during primary HIV infection (PHI). METHOD: Eight patients were followed from a median of 5 days from the onset of PHI illness. Plasma HIV-1 RNA levels were measured frequently and the results were fitted to mathematical models. HIV-1 RNA levels were also monitored in nine patients given two reverse transcriptase inhibitors and a protease inhibitor after a median of 7 days from the onset of PHI illness. RESULTS:HIV-1 RNA appeared in the blood during the week preceding onset of PHI illness and increased rapidly during the first viremic phase, reaching a peak at a mean of 7 days after onset of illness. This was followed by a phase of rapidly decreasing levels of HIV-1 RNA to an average of 21 days after onset. Viral density continued to decline thereafter but at a 5- to 50-fold lower rate; a steady-state level was reached at a median of 2 months after onset of PHI. Peak viral density levels correlated significantly with levels measured between days 50 and 600. Initiation of antiretroviral treatment during PHI resulted in rapidly declining levels to below 50 copies/mL. CONCLUSIONS: This study demonstrates the kinetic phases of viremia during PHI and indicates two new contributions to the natural history of HIV-1 infection: PHI peak levels correlate with steady-state levels and HIV-1 RNA declines biphasically; an initial rapid decay is usually followed by a slow decay, which is similar to the initial changes seen with antiviral treatment.
Authors: Andrew C Young; Constantin T Yiannoutsos; Manu Hegde; Evelyn Lee; Julia Peterson; Rudy Walter; Richard W Price; Dieter J Meyerhoff; Serena Spudich Journal: Neurology Date: 2014-09-26 Impact factor: 9.910
Authors: Taha E Taha; Maria M James; Donald R Hoover; Jin Sun; Oliver Laeyendecker; Caroline E Mullis; Johnstone J Kumwenda; Jairam R Lingappa; Bertran Auvert; Charles S Morrison; Lynne M Mofensen; Allan Taylor; Mary G Fowler; Newton I Kumenda; Susan H Eshleman Journal: AIDS Date: 2011-07-17 Impact factor: 4.177
Authors: Stephanie J Bissel; Julia Kofler; Julia Nyaundi; Michael Murphey-Corb; Stephen R Wisniewski; Clayton A Wiley Journal: J Neuroimmune Pharmacol Date: 2016-04-08 Impact factor: 4.147
Authors: Merlin L Robb; Leigh A Eller; Hannah Kibuuka; Kathleen Rono; Lucas Maganga; Sorachai Nitayaphan; Eugene Kroon; Fred K Sawe; Samuel Sinei; Somchai Sriplienchan; Linda L Jagodzinski; Jennifer Malia; Mark Manak; Mark S de Souza; Sodsai Tovanabutra; Eric Sanders-Buell; Morgane Rolland; Julie Dorsey-Spitz; Michael A Eller; Mark Milazzo; Qun Li; Andrew Lewandowski; Hao Wu; Edith Swann; Robert J O'Connell; Sheila Peel; Peter Dawson; Jerome H Kim; Nelson L Michael Journal: N Engl J Med Date: 2016-05-18 Impact factor: 91.245
Authors: Jesus F Salazar-Gonzalez; Maria G Salazar; Brandon F Keele; Gerald H Learn; Elena E Giorgi; Hui Li; Julie M Decker; Shuyi Wang; Joshua Baalwa; Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; M Brad Guffey; Katharine J Bar; Katie L Davis; Christina Ochsenbauer-Jambor; John C Kappes; Michael S Saag; Myron S Cohen; Joseph Mulenga; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Martin Markowitz; Peter Hraber; Alan S Perelson; Tanmoy Bhattacharya; Barton F Haynes; Bette T Korber; Beatrice H Hahn; George M Shaw Journal: J Exp Med Date: 2009-06-01 Impact factor: 14.307